AR and prostate carcinoma: Treatment of abiraterone-resistant prostate cancer cells with indomethacin, a small-molecule AKR1C3 inhibitor, restores and even increases the sensitivity of prostate cancer cells to abiraterone therapy, while reducing intracrine androgen levels and AR transcriptional activity15,.30